What is the role of betrixaban (Bevyxxa) in the treatment of deep venous thrombosis (DVT)?

Updated: Jun 06, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print
Answer

Betrixaban (Bevyxxa), a FXa inhibitor, was approved by the FDA in June 2017. [133] It is indicated for the prophylaxis of VTE in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors that may cause VTE. [133]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!